|
nasdaq:insy
|
1216292
|
Nov 14th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 13th, 2023 10:57PM
|
Nov 13th, 2023 10:57PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 13th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 12th, 2023 10:36PM
|
Nov 13th, 2023 06:20PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 12th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 11th, 2023 10:45PM
|
Nov 11th, 2023 10:45PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 11th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 10th, 2023 10:42PM
|
Nov 11th, 2023 06:30PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 10th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 10th, 2023 07:39AM
|
Nov 10th, 2023 12:07PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 9th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 8th, 2023 10:45PM
|
Nov 9th, 2023 11:49AM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 8th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 7th, 2023 10:46PM
|
Nov 7th, 2023 10:46PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 7th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 6th, 2023 10:19PM
|
Nov 6th, 2023 10:19PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 6th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 5th, 2023 10:09PM
|
Nov 6th, 2023 01:03PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:insy
|
1216292
|
Nov 5th, 2023 12:00AM
|
Insys Therapeutics, Inc.
|
10K
|
68.00
|
Open
|
|
Nov 4th, 2023 11:25PM
|
Nov 5th, 2023 01:50PM
|
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.
Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
|
Open
|
|
Open
|
444 South Ellis Road
|
Chandler
|
Arizona
|
US
|
85224
|
|
Insys Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|